Nitric oxide and almitrine: the definitive answer for hypoxemia

Area of Science:

• Pulmonary Medicine
• Critical Care Medicine
• Pharmacology

Background:

• Acute lung injury (ALI) often causes hypoxia due to abnormal ventilation/perfusion (V/Q) ratios.
• Pharmacological interventions targeting pulmonary blood flow distribution can potentially correct hypoxia.
• Inhaled nitric oxide (iNO) therapy demonstrated this concept but had a significant non-responder rate.

Purpose of the Study:

• To evaluate the efficacy of combining inhaled nitric oxide with almitrine bismesylate in ALI patients.
• To assess the impact of this combination therapy on oxygenation and pulmonary shunting.

Main Methods:

• Review of studies involving ALI or acute respiratory distress syndrome (ARDS) patients treated with iNO and almitrine bismesylate.
• Analysis of reported changes in partial pressure of oxygen (PaO2) and pulmonary shunt fraction.

Main Results:

• The combination of iNO and almitrine bismesylate demonstrated significant improvements in PaO2.
• This combination therapy led to a substantial reduction in pulmonary shunt.
• The response rate to the combination therapy appeared higher than to either agent alone.

Conclusions:

• Pulmonary blood flow manipulation is a key strategy for correcting severe hypoxia in ALI.
• The combination of inhaled nitric oxide and almitrine bismesylate offers a promising therapeutic approach for ALI patients with hypoxia.
• This combination therapy may overcome the limitations of monotherapy with iNO.